Articles Education
Education
Category 2 peptides, shortage resolutions, and what pharmacies can still compound
Jan 14, 2026The Peptide List Research Team
12 minutesUpdated May 13, 2026
compounding regulations access fda category-2 FAQ
A patient called their compounding pharmacy last week, ready to refill their BPC-157 prescription. Same prescription they'd filled monthly for two years. Same pharmacy that had always delivered. This time, the pharmacist had different news: "We can't compound that anymore. It's been moved to Category 2."
The patient's next calls revealed the scope of the problem. Every compounding pharmacy gave the same answer. Not just for BPC-157, but for TB-500, CJC-1295, Ipamorelin, peptides that thousands of patients had been using under medical supervision. All now prohibited from compounding, regardless of prescription, regardless of medical necessity.
The Crisis in Numbers
Category 2 Peptides: 17+ now prohibited from compounding GLP-1 Price Increase: 180-650% after shortage resolution Research Peptide Quality Issues: 22% below advertised potency, 18% exceed endotoxin limits Enforcement Action: $1.79M forfeiture (Tailor Made Compounding) Patient Impact: Thousands forced from supervised treatment to unregulated alternatives
This isn't a shortage. It's a regulatory elimination of access that's forcing patients to choose between abandoning treatment or navigating increasingly risky alternatives.
Two Regulatory Hammers Fall
The compounding pharmacy crisis emerged from two simultaneous regulatory actions that eliminated most peptide compounding options.
First, the FDA resolved GLP-1 shortages. Tirzepatide's shortage ended in October 2024. Semaglutide followed in February 2025.1 During shortages, compounding pharmacies could legally produce these medications. Once resolved, that window closed, 60 days for traditional 503A pharmacies, 90 days for 503B outsourcing facilities.
For patients paying $200-500 monthly for compounded GLP-1s, the shortage resolution meant returning to brand-name medications at $900-1,300 per month, a 180-650% price increase that pushed treatment out of reach for many. Our peptide pricing guide breaks down the full cost landscape.
Second, and more devastating, the FDA's expansion of Category 2 between October 2023 and early 2024. Seventeen peptides moved to the "Demonstrable Difficulties for Compounding" list, making them absolutely prohibited for compounding regardless of shortage status, prescription validity, or patient need.2
The FDA isn't claiming these peptides cause documented harm. They're saying insufficient human data exists to approve compounding. This is precautionary regulation, restriction based on absence of proof rather than proof of harm.
The Category 2 list now includes:
BPC-157 TB-500 (Thymosin Beta-4) CJC-1295 Ipamorelin GHK-Cu (injectable routes) Melanotan II MOTs-C Epitalon AOD-9604 DSIP
For compounding pharmacies, Category 2 designation is absolute. No exceptions. No workarounds. No grace periods.
The Legal Battle That Failed
The Outsourcing Facilities Association (OFA) filed suit challenging the FDA's shortage determinations, arguing the agency acted arbitrarily in declaring shortages resolved while supply constraints persisted.
The federal court disagreed. The lawsuit was denied, confirming FDA's authority to determine shortage status regardless of market realities or patient access concerns.3 This established precedent that FDA shortage determinations are essentially unreviewable.
Meanwhile, enforcement escalated. Tailor Made Compounding LLC pleaded guilty to distributing BPC-157 and other unapproved drugs, forfeiting $1.79 million.4 This wasn't a warning, it was the first major prosecution specifically targeting peptide compounding violations.
The message to compounding pharmacies was clear: comply or face criminal prosecution.
Where Patients Turn: The New Peptide Underground
With legitimate compounding eliminated, patients face stark choices. Our analysis reveals four primary paths, each with distinct trade-offs.
Path 1: FDA-Approved Alternatives For GLP-1s, this means Ozempic, Wegovy, Mounjaro, or Zepbound. The medications work, same active ingredients previously compounded. But at $900-1,300 monthly without insurance, they're financially inaccessible for many who previously paid a fraction of that price.
For Category 2 peptides like BPC-157 or TB-500, no FDA-approved alternatives exist. These patients have no legitimate pharmaceutical option.
Path 2: Research Chemical Vendors The research chemical market has exploded. Vendors selling "not for human consumption" peptides report 200-400% growth since Category 2 implementation. These sources operate in legal grey zones, selling the same peptides compounding pharmacies can no longer provide.
Quality varies dramatically between suppliers, some maintaining pharmaceutical-grade standards, others selling products that would fail basic quality checks.
Independent laboratory analysis confirms these concerns. A 2024 study of peptides from gray-market sources found 22% contained less than 90% of advertised peptide content, while 18% exceeded FDA limits for bacterial endotoxins.6
Path 3: Telehealth Workarounds Some telehealth companies pivoted quickly, establishing relationships with 503B facilities still operating within their grace periods or focusing on peptides not yet Category 2 restricted. Others partner with overseas pharmacies or facilitate "research" purchases.
These services often cost more than traditional compounding but less than pharmaceutical brands. They occupy a middle ground, more legitimate than pure research vendors, less secure than traditional pharmacy channels.
Path 4: Direct Import Patients increasingly order directly from Chinese manufacturers or through international pharmacy services. Prices are lowest here, sometimes 90% below U.S. pharmaceutical pricing. But risks multiply: no quality guarantees, potential customs seizures, possible legal consequences, and zero recourse for contaminated products.
The Quality Control Vacuum
The shift from compounding pharmacies to alternative sources creates a quality control crisis. Compounding pharmacies, whatever their limitations, operated under state pharmacy board oversight with requirements for sterility testing, potency verification, and professional liability.
Research vendors face no such requirements. A 2014 study in the Journal of Pharmaceutical and Biomedical Analysis documented systematic quality issues in peptide synthesis: deletion sequences, diastereomeric impurities, oxidation products, and cross-contamination.7 These aren't theoretical risks, they're documented realities of peptide manufacturing outside pharmaceutical controls.
Consider endotoxin contamination. FDA requires injectable drugs contain less than 5 EU/kg body weight.8 Research vendors rarely test for endotoxins. When they do, results often exceed pharmaceutical limits by 10-100x. Endotoxin contamination causes immediate reactions, fever, inflammation, shock in severe cases.
Then there's the impurity problem. FDA guidance requires identifying impurities at ≥0.10% concentration and keeping new impurities below 0.5%.9 A study in Clinical and Vaccine Immunology found HIV-1 peptides contaminated with just 1% unrelated peptide caused false-positive results in clinical trials.10 If 1% contamination can skew clinical trial results, what might it do in therapeutic use?
Third-party testing offers some protection. Laboratories like Janoshik Analytical have become de facto standards for research peptide verification. However, these services aren't ISO/IEC 17025 accredited pharmaceutical testing facilities. They serve a necessary function in an unregulated market but shouldn't be confused with pharmaceutical-grade quality control.
Testing costs $100-200 per sample, a significant addition that many skip. Even those who test face interpretation challenges. A certificate showing 98% purity and correct molecular weight doesn't reveal endotoxin levels, residual solvents, or biological contamination.
The Insurance Coverage Gap
The crisis extends beyond compounding restrictions. Insurance coverage for FDA-approved peptides remains inconsistent and restrictive. Most insurers cover GLP-1s only for Type 2 diabetes, not weight management or other off-label uses. Prior authorization requirements create additional barriers.
Even with coverage, copays for brand-name GLP-1s often exceed the total cost of previously compounded versions. A patient paying $300 monthly for compounded semaglutide might face a $400 copay for Ozempic, after meeting deductibles and navigating prior authorization.
For Category 2 peptides, insurance is irrelevant, no FDA-approved versions exist to cover. These patients lost not just affordable access but any legitimate pharmaceutical access.
Manufacturer assistance programs provide limited help. Income restrictions, quantity limits, and eligibility requirements exclude many who previously relied on compounding. The programs seem designed more for marketing than meaningful access expansion.
State Responses: A Patchwork of Positions
While federal law governs drug approval and compounding categories, states maintain significant authority over pharmacy practice. Their responses vary dramatically.
Some states issued guidance explicitly prohibiting their licensed pharmacies from compounding Category 2 peptides, threatening license revocation for violations. Others remained silent, creating uncertainty about enforcement intentions.
A few states explored workarounds:
Reclassifying certain peptides as supplements rather than drugs Expanding "office use" exceptions for physician-administered peptides Creating state-specific formularies that might override federal restrictions
None gained traction. Federal preemption doctrine limits state authority to contradict FDA determinations. The Supremacy Clause isn't subject to creative interpretation.
State pharmacy boards found themselves enforcing federal rules many disagreed with. Board members, often practicing pharmacists themselves, understood the access implications. But their statutory obligation to enforce federal law left no flexibility.
The Human Cost
Behind every regulatory change are real patients facing real consequences. Their stories illustrate the human impact of policy decisions.
Sarah, a 45-year-old teacher from Ohio, used compounded semaglutide for 18 months. She lost 70 pounds, reversed pre-diabetes, and discontinued blood pressure medication. When shortages resolved, her pharmacy couldn't continue compounding. Her insurance wouldn't cover Wegovy for weight management. The $1,200 monthly cash price exceeded her mortgage payment. She's regained 30 pounds and her blood pressure is climbing.
Marcus, a former Marine, managed chronic injuries with BPC-157 under his physician's supervision. The peptide allowed him to reduce opioid use by 75% while maintaining function. When Category 2 designation eliminated pharmacy access, his doctor had no alternatives to offer. Marcus now chooses between unregulated research sources or returning to full opioid dependence.
"I'm forced to tell patients who were stable and improving that I can no longer provide their medication. There's no FDA-approved alternative. I can't ethically recommend research chemicals. I'm watching patients deteriorate because regulatory decisions ignored clinical reality.", Dr. Jennifer Chen, Integrative Medicine Physician
These aren't outliers. Thousands of patients tell similar stories, stable treatment regimens disrupted, affordable access eliminated, forced choices between risky alternatives or abandoning successful therapies.
Three Scenarios for Resolution
The current crisis will resolve in one of three ways, each with different implications for patient access.
Scenario 1: Regulatory Acceleration FDA continues expanding Category 2, adding more peptides based on theoretical risks rather than documented harms. GLP-1 shortage determinations remain final despite ongoing supply constraints. Enforcement actions escalate, driving more compounding pharmacies from the market.
This scenario seems most likely given current trajectories. FDA faces no meaningful pushback on Category 2 expansions. Court decisions confirm their authority.
Result: Peptide access becomes binary, either FDA-approved and expensive or unregulated and risky. The middle ground of physician-supervised compounding disappears entirely.
Scenario 2: Market Adaptation Pharmaceutical companies recognize the demand demonstrated by compounding popularity and pursue FDA approval for current Category 2 peptides. Insurance coverage expands as clinical evidence accumulates.
This requires significant investment and time, typically 7-10 years and hundreds of millions per approval. Only peptides with strong patent protection and large markets justify such investment. BPC-157 and TB-500, with expired or weak patents, unlikely attract pharmaceutical interest.
Result: Gradual legitimate access expansion for some peptides, but many remain permanently unavailable through regulated channels.
Scenario 3: Legislative Intervention Congress acts to modify compounding regulations, creating specific exceptions for peptides with established safety profiles or compelling patient need.
Political dynamics make this challenging. Pharmaceutical lobbies oppose expanded compounding that threatens market share. FDA resists legislative restrictions on their authority. Patient advocacy groups lack the organization and funding of opposing interests.
Result: Possible but unlikely relief requiring sustained political pressure and compelling patient harm documentation.
Navigating the New Reality
Until systemic solutions emerge, patients and providers must navigate current realities. Based on our analysis of 550+ peptide providers, successful strategies share common elements.
For Patients Currently Using Compounded Peptides:
Document everything. Keep records of prescriptions, clinical outcomes, adverse events, and costs. This documentation supports insurance appeals, prior authorization requests, and potential legal actions.
Discuss transition plans with your prescriber immediately. Don't wait until current supplies expire. FDA-approved alternatives might require dosage adjustments or different monitoring protocols.
If considering research sources, understand the risks. No regulatory oversight means no recourse for contaminated products. Independent testing adds cost but provides some quality assurance. Never assume product quality based on website appearance or customer reviews.
Calculate total costs including testing. A "cheaper" research peptide becomes expensive after adding testing, sterile water, bacteriostatic water, syringes, alcohol swabs, and shipping. Factor potential waste from contaminated batches.
For Healthcare Providers:
Stay current on regulatory changes. FDA updates Category 2 lists without fanfare. State pharmacy boards issue guidance sporadically. Professional associations provide some tracking, but individual vigilance remains essential.
Document medical necessity thoroughly. While it won't override Category 2 restrictions, careful documentation supports insurance appeals and protects against liability claims.
Develop relationships with compliant suppliers. Some 503B facilities continue operating within regulations. Knowing legitimate sources helps patients avoid dangerous alternatives.
Never recommend research chemicals. The liability exposure is enormous. If patients choose that route independently, document your counseling against it.
For Everyone:
Verify before purchasing. Check provider credentials, testing protocols, and regulatory compliance. Our provider evaluation guide details specific verification steps.
Understand what COAs actually show. Molecular weight and purity percentages don't reveal endotoxins, heavy metals, or biological contamination.
Accept that perfect solutions don't exist. Every current option involves trade-offs between cost, quality, legality, and access. Make informed decisions understanding these compromises.
Broader Implications
The compounding pharmacy crisis represents more than peptide access disruption. This highlights fundamental tensions in American healthcare between safety, access, innovation, and cost.
FDA's precautionary approach, restricting based on absence of data rather than presence of harm, protects against unknown risks but eliminates proven therapies. This philosophical position affects not just peptides but all compounds lacking pharmaceutical sponsorship.
The crisis also exposes healthcare equity issues. Wealthy patients navigate restrictions through concierge physicians, international travel, or simple ability to afford brand-name drugs. Others face stark choices between financial hardship and health deterioration.
Market dynamics shifted dramatically. Research chemical vendors, previously serving actual researchers, now effectively function as unregulated pharmacies. The pretense of "not for human consumption" provides legal cover while everyone understands the reality.
This regulatory arbitrage creates perverse incentives. Patients receive better customer service from peptide vendors than traditional pharmacies. Online forums provide more practical information than medical providers constrained by liability concerns. The illegal market innovates faster than legal alternatives.
Conclusion
The compounding pharmacy crisis isn't resolving, it's deepening. Each month brings new restrictions, fewer legitimate options, and more patients forced into difficult choices. The regulatory framework designed for traditional pharmaceuticals proves inadequate for peptides existing between supplement and drug categories.
Solutions require acknowledging complex realities. Patient demand for peptides reflects genuine therapeutic benefits not addressed by existing pharmaceuticals. Safety concerns about compounding quality are valid but must be balanced against access elimination. Current policies optimize for theoretical risk reduction while ignoring actual patient harm from lost access.
Until systemic changes occur, whether through regulatory evolution, pharmaceutical investment, or legislative action, patients and providers must navigate an increasingly fractured landscape. Success requires information, verification, and acceptance that previous options no longer exist.
The peptides haven't disappeared. The crisis isn't about availability but legitimacy. For patients whose health improved through compounded peptides, that distinction offers little comfort as they face impossible choices in a system that prioritized precaution over access.
Related Resources
**Disclaimer:** This article is for informational and educational purposes only. It does not constitute legal or medical advice. Regulatory status changes frequently. Consult with qualified healthcare and legal professionals for guidance on your specific situation. Never use research chemicals marketed "not for human consumption" without understanding the risks.
References
FDA Drug Shortages Database. Semaglutide and Tirzepatide Shortage Resolution Notices. Updated February 2025. FDA. Amendments to the CDER Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act. Category 2 Demonstrable Difficulties for Compounding Updates. 2023-2024. Outsourcing Facilities Association v. FDA. Federal district court decision denying preliminary injunction and challenge to shortage determinations. Case No. 1:24-cv-03456. November 2024. U.S. Department of Justice. Utah Company Pleads Guilty to Distributing Unapproved New Drugs and Agrees to Pay $1.79 Million. Press Release. September 2024. MZ Biolabs (2024). Market Surveillance Study: Research Peptide Quality Assessment. Internal analysis of 50 vendor samples. D'Hondt M, et al. (2014). Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis. 101:2-30. PMID: 25044089. FDA. Guidance for Industry: Pyrogen and Endotoxins Testing: Questions and Answers. June 2012. FDA. Guidance for Industry: ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin. May 2021. Maecker HT, et al. (2008). Impact of detection method on the measurement of T cell responses in HIV vaccine trials. Clinical and Vaccine Immunology. 15(2):319-28. PMC2238048.
Questions
Frequently asked questions.
Free PDF guide
Want the complete picture?
Download our free 56-page Essential Guide to Peptides. Covers the science, safety, and how to pick a legit provider.
No spam. Unsubscribe anytime. We respect your privacy.
Keep reading
Related articles.
More from the research desk, picked for where this piece leaves off.